Campaign for Patient Access Click here to see what you can do! The purpose of the Chapter is to contribute to the prevention of cardiovascular diseases and to ensure optimal quality of care for individuals with such diseases. In carrying out these purposes, the Chapter functions, in consultation with the leadership of the College, as a source of advice to local and state governmental and professional organizations concerning issues related to cardiovascular disease. The Chapter, in the interest of patients, physicians, and the public in general, maintains a high level of social consciousness and involvement with socioeconomic factors and access to the highest possible quality of cardiovascular health care. Wear RED Day - February 3rd!  ____________________________________________________________________________________________________________ Helpful Hints for documenting Level 4 visits for the ongoing CMS audit For those of you from whom documentation has been requested to support billing Medicare for a 99214 visit, the following will be useful: 1. Obviously, full documentation in the first place is crucial. 2.  If you are not using EHR make certain that the chart entries are legible… if not, then submit an annotated note with the photocopy of the submitted encounter note “translating” the chart entries so the nurse reviewer can decipher the handwriting. 3.  Along with the copy of the patient encounter note, submit copies of materials that support the billed level of service; for example, a copy of an ECG performed that date and reviewed as part of the visit; copies of radiologic, ultrasound, and laboratory reports reviewed incident to that day’s service; etc. 4.  If the signature is illegible, submit an attestation that the billing provider indeed performed the billed service that day. 5.  You can also submit documentation of follow-up phone calls attributable to the service date under review; if you chart subsequent interactions with a patient or their family, and that interaction is related to the billed service (eg. reviewing laboratory results over the phone), then that interaction counts toward the time and complexity for the initial  billed visit. National Coverage Determination (NCD) for Percutaneous Transluminal Angioplasty (20.7) Concurrent with Carotid Artery Stenting in Patients at High Risk for Carotid Endarterectomy This special edition MLN Matters article (SE 1119) contains no changes to current policy. This article clarifies current policies regarding Percutaneous Transluminal Angioplasty (PTA) and Carotid Artery Stenting (CAS). The National Coverage Determination (NCD 20.7 for PTA of the carotid artery concurrent with stenting is not changed by the new FDA-approved indications for the RX Acculink carotid stent in patients who are not at high risk for Carotid Endarterectomy (CEA). Providers are encouraged to review the information and to share with their staff. http://www.palmettogba.com/palmetto/providers.nsf/ls/J1B~8HKLML2250?opendocument&utm_source=J1BL&utm_campaign=J1BLs&utm_medium=email   Important:! Cuts for not e-prescribing coming soon to your membership! For questions regarding selecting and purchasing an e-prescribing system, please contact ACC’s Health Information Technology Department at jkreuter@acc.org. For more information regarding Medicare’s e-prescribing program and requirements, please contact ACC’s Advocacy Division at (800) 435-9203 or via e-mail at advodiv@acc.org.